344 related articles for article (PubMed ID: 29217527)
1. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
Colunga A; Pulliam T; Nghiem P
Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527
[TBL] [Abstract][Full Text] [Related]
2. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
Miller NJ; Church CD; Fling SP; Kulikauskas R; Ramchurren N; Shinohara MM; Kluger HM; Bhatia S; Lundgren L; Cheever MA; Topalian SL; Nghiem P
J Immunother Cancer; 2018 Nov; 6(1):131. PubMed ID: 30482247
[TBL] [Abstract][Full Text] [Related]
3. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Vandeven N; Nghiem P
Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
[TBL] [Abstract][Full Text] [Related]
4. Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer.
Akaike T; Nghiem P
J Dermatol Sci; 2022 Jan; 105(1):2-10. PubMed ID: 34836718
[TBL] [Abstract][Full Text] [Related]
5. Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood.
Iyer JG; Afanasiev OK; McClurkan C; Paulson K; Nagase K; Jing L; Marshak JO; Dong L; Carter J; Lai I; Farrar E; Byrd D; Galloway D; Yee C; Koelle DM; Nghiem P
Clin Cancer Res; 2011 Nov; 17(21):6671-80. PubMed ID: 21908576
[TBL] [Abstract][Full Text] [Related]
6. Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.
Tabachnick-Cherny S; Pulliam T; Church C; Koelle DM; Nghiem P
Mol Carcinog; 2020 Jul; 59(7):807-821. PubMed ID: 32219902
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.
Ricci C; Righi A; Ambrosi F; Gibertoni D; Maletta F; Uccella S; Sessa F; Asioli S; Pellilli M; Maragliano R; La Rosa S; Papotti MG; Asioli S
Endocr Pathol; 2020 Mar; 31(1):21-32. PubMed ID: 31808008
[TBL] [Abstract][Full Text] [Related]
8. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
[TBL] [Abstract][Full Text] [Related]
9. Insights into anti-tumor immunity
Jani S; Church CD; Nghiem P
Front Immunol; 2023; 14():1172913. PubMed ID: 37287968
[TBL] [Abstract][Full Text] [Related]
10. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
11. Merkel Cell Carcinoma Therapeutic Update.
Cassler NM; Merrill D; Bichakjian CK; Brownell I
Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
[TBL] [Abstract][Full Text] [Related]
12. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.
Afanasiev OK; Yelistratova L; Miller N; Nagase K; Paulson K; Iyer JG; Ibrani D; Koelle DM; Nghiem P
Clin Cancer Res; 2013 Oct; 19(19):5351-60. PubMed ID: 23922299
[TBL] [Abstract][Full Text] [Related]
13. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus.
Rodig SJ; Cheng J; Wardzala J; DoRosario A; Scanlon JJ; Laga AC; Martinez-Fernandez A; Barletta JA; Bellizzi AM; Sadasivam S; Holloway DT; Cooper DJ; Kupper TS; Wang LC; DeCaprio JA
J Clin Invest; 2012 Dec; 122(12):4645-53. PubMed ID: 23114601
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6-7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A.
Guadagni S; Farina AR; Cappabianca LA; Sebastiano M; Maccarone R; Zelli V; Clementi M; Chiominto A; Bruera G; Ricevuto E; Fiorentini G; Sarti D; Mackay AR
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153070
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
16. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma.
Wardhani LO; Matsushita M; Iwasaki T; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
Hum Pathol; 2019 Feb; 84():52-61. PubMed ID: 30240768
[TBL] [Abstract][Full Text] [Related]
17. Robust Production of Merkel Cell Polyomavirus Oncogene Specific T Cells From Healthy Donors for Adoptive Transfer.
Davies SI; Barrett J; Wong S; Chang MJ; Muranski PJ; Brownell I
Front Immunol; 2020; 11():592721. PubMed ID: 33362774
[TBL] [Abstract][Full Text] [Related]
18. Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.
Gavvovidis I; Leisegang M; Willimsky G; Miller N; Nghiem P; Blankenstein T
Clin Cancer Res; 2018 Aug; 24(15):3644-3655. PubMed ID: 29669806
[No Abstract] [Full Text] [Related]
19. Characterization of the Impact of Merkel Cell Polyomavirus-Induced Interferon Signaling on Viral Infection.
Wang R; Yang JF; Senay TE; Liu W; You J
J Virol; 2023 Apr; 97(4):e0190722. PubMed ID: 36946735
[TBL] [Abstract][Full Text] [Related]
20. Conversion of Sox2-dependent Merkel cell carcinoma to a differentiated neuron-like phenotype by T antigen inhibition.
Harold A; Amako Y; Hachisuka J; Bai Y; Li MY; Kubat L; Gravemeyer J; Franks J; Gibbs JR; Park HJ; Ezhkova E; Becker JC; Shuda M
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20104-20114. PubMed ID: 31527246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
